Overview

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Status:
Completed
Trial end date:
2021-02-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin, Inc.
Treatments:
Antibodies, Monoclonal
Mogamulizumab
Vorinostat